READ the full study in RAPM: #PhantomLimbPain #Cryoneurolysis #PainMedicine #RegionalAnesthesia #ClinicalResearch #Innovation To view or add a comment, sign in Ophthopedia Update:Mitomycin C in Non-Endoscopic Endonasal Dacryocystorhinostomy: A Randomized Clinical Trial involving 442 cases: Mitomycin C (MMC) is used as an adjuvant in endonasal endoscopic dacryocystorhinostomy (EN-DCR) despite the existing heterogeneity in the literature on the concentration, duration of application, indication and outcomes
Certificate of Analysis (COA) Every SinoPepLab BPC-157 batch is supplied with a Certificate of Analysis (COA)
A Category 1 listing only means a compound can be legally prepared by 503A compounding pharmacies it does not make BPC-157 an FDA-approved drug
At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity
BPC 157 Before And After BPC 157 peptide powder before and after results are often discussed anecdotally by users and researchers, especially in the context of healing injuries, reducing inflammation, and improving tissue regeneration
VIP (Vasoactive Intestinal Peptide) : Neurologic peptide that can reduce systemic inflammation and promote brain healing
